Abstract
“Metabolic treatment” involves the use of drugs to improve cardiomyocyte function. Trimetazidine is the most investigated drugs in this group. The ESC 2006 guidelines on the management of patients with stable angina mention the efficacy of metabolic treatment in improving physical efficiency and decreasing the recurrence of pain. The available data suggest that combined therapy of trimetazidine and haemodynamic drugs is an effective antianginal treatment that reduces the risk of pain recurrence (in as many as 64% of patients). The most recent studies also suggest that trimetazidine might be effective in patients with acute coronary syndromes, ischemic cardiomyopathy and heart failure. However, while trimetazidine has shown beneficial effects on surrogate endpoints in several small trials its effect on cardiovascular events is uncertain. Further large randomized studies are needed before its effects on cardiovascular events can be evaluated.
Keywords: Acute coronary syndromes, metabolic treatment, trimetazidine
Current Vascular Pharmacology
Title: The Role of Trimetazidine After Acute Myocardial Infarction
Volume: 6 Issue: 4
Author(s): Maciej Banach, Jacek Rysz, Aleksander Goch, Dimitri P. Mikhailidis and Giuseppe M.C. Rosano
Affiliation:
Keywords: Acute coronary syndromes, metabolic treatment, trimetazidine
Abstract: “Metabolic treatment” involves the use of drugs to improve cardiomyocyte function. Trimetazidine is the most investigated drugs in this group. The ESC 2006 guidelines on the management of patients with stable angina mention the efficacy of metabolic treatment in improving physical efficiency and decreasing the recurrence of pain. The available data suggest that combined therapy of trimetazidine and haemodynamic drugs is an effective antianginal treatment that reduces the risk of pain recurrence (in as many as 64% of patients). The most recent studies also suggest that trimetazidine might be effective in patients with acute coronary syndromes, ischemic cardiomyopathy and heart failure. However, while trimetazidine has shown beneficial effects on surrogate endpoints in several small trials its effect on cardiovascular events is uncertain. Further large randomized studies are needed before its effects on cardiovascular events can be evaluated.
Export Options
About this article
Cite this article as:
Banach Maciej, Rysz Jacek, Goch Aleksander, Mikhailidis P. Dimitri and Rosano M.C. Giuseppe, The Role of Trimetazidine After Acute Myocardial Infarction, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909788
DOI https://dx.doi.org/10.2174/157016108785909788 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sudden Unexpected Death in Infancy and the Dilemma of Defining the Sudden Infant Death Syndrome
Current Pediatric Reviews Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool?
Current Pharmaceutical Design Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges
CNS & Neurological Disorders - Drug Targets Glucocorticoid Analogues: Potential Therapeutic Alternatives for Treating Inflammatory Muscle Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses
Current Drug Targets - CNS & Neurological Disorders Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Epidemiology and Risk Factors of Cerebral Ischemia and Ischemic Heart Diseases: Similarities and Differences
Current Cardiology Reviews Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Uric Acid and Oxidative Stress
Current Pharmaceutical Design Biomarkers in Acute Heart Failure Syndromes: An Update
Current Cardiology Reviews Bioinformatics Tools for Mass Spectrometry-Based High-Throughput Quantitative Proteomics Platforms
Current Proteomics Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery